Merck China's Oncology Business Unit Head Departs, Successor Not Yet Announced

On the 16th, rumors of executive changes within the industry were confirmed.

MSD China Announces That Mou Yanping, Head of the Oncology Business Unit, Has Decided to Leave the Company to Pursue External Career Opportunities, with Her Last Working Day Being the 25th of This Month

Mou Yanping joined MSD China at the inception of its Oncology Business Unit and has been with the company for three years. She established and currently leads the MSD China Oncology Marketing team, as well as the sales teams for KEYTRUDA (pembrolizumab), Tislelizumab, and LENVIMA (lenvatinib). During her tenure, three major new products were launched, including MSD’s KEYTRUDA, as well as AstraZeneca’s LYNPARZA and Eisai’s LENVIMA through collaborative partnerships. Last year, MSD China’s oncology business achieved robust growth, recording sales exceeding USD 500 million.

MSD China has not yet announced a successor for its Oncology Division.

(Note: The original text has been abridged.)

Original Title: MSD China's Oncology Division Appoints New Head!